Wellgistics Health (WGRX)
Market Price (1/21/2026): $0.389 | Market Cap: $28.9 MilSector: Consumer Staples | Industry: Drug Retail
Wellgistics Health (WGRX)
Market Price (1/21/2026): $0.389Market Cap: $28.9 MilSector: Consumer StaplesIndustry: Drug Retail
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 496% | Weak multi-year price returns2Y Excs Rtn is -132%, 3Y Excs Rtn is -160% | Penny stockMkt Price is 0.4 |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -72 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -212% | |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 76% | ||
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -47% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 163% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -23% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -272% | ||
| High stock price volatilityVol 12M is 260% | ||
| Key risksWGRX key risks include [1] poor financial health and high leverage that raise substantial doubt about its ability to continue as a going concern and [2] a potential delisting from Nasdaq for failing to meet the minimum bid price requirement. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 496% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% |
| Weak multi-year price returns2Y Excs Rtn is -132%, 3Y Excs Rtn is -160% |
| Penny stockMkt Price is 0.4 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -72 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -212% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 76% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -47% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 163% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -23% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -272% |
| High stock price volatilityVol 12M is 260% |
| Key risksWGRX key risks include [1] poor financial health and high leverage that raise substantial doubt about its ability to continue as a going concern and [2] a potential delisting from Nasdaq for failing to meet the minimum bid price requirement. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Wellgistics Health (WGRX) stock has lost about 55% since 9/30/2025 because of the following key factors:
1. Dilutive Public Offering at Low Valuation: Wellgistics Health executed a public offering on September 25, 2025, pricing 7.14 million shares at just $0.70 per share. This significant dilution at a depressed price point caused the stock to tumble, signaling a substantial devaluation of existing shares and a negative market reaction to the company's capital raising efforts.
2. Significant Worsening of Financial Performance: The company reported a dramatically increased net loss, jumping from -$6.67 million in the second quarter of 2025 to a much larger -$34.32 million in the third quarter of 2025. This steep increase in losses indicated deteriorating financial health and raised concerns about the company's operational efficiency and ability to achieve profitability.
Show more
1. Dilutive Public Offering at Low Valuation: Wellgistics Health executed a public offering on September 25, 2025, pricing 7.14 million shares at just $0.70 per share. This significant dilution at a depressed price point caused the stock to tumble, signaling a substantial devaluation of existing shares and a negative market reaction to the company's capital raising efforts.
2. Significant Worsening of Financial Performance: The company reported a dramatically increased net loss, jumping from -$6.67 million in the second quarter of 2025 to a much larger -$34.32 million in the third quarter of 2025. This steep increase in losses indicated deteriorating financial health and raised concerns about the company's operational efficiency and ability to achieve profitability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -44.2% change in WGRX stock from 10/31/2025 to 1/20/2026 was primarily driven by a -27.6% change in the company's P/S Multiple.| 10312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 0.70 | 0.39 | -44.22% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 36.74 | 34.08 | -7.24% |
| P/S Multiple | 1.18 | 0.85 | -27.59% |
| Shares Outstanding (Mil) | 61.77 | 74.38 | -20.41% |
| Cumulative Contribution | -46.55% |
Market Drivers
10/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| WGRX | -44.2% | |
| Market (SPY) | -0.7% | 26.6% |
| Sector (XLP) | 8.0% | 5.6% |
Fundamental Drivers
The -55.1% change in WGRX stock from 7/31/2025 to 1/20/2026 was primarily driven by a -45.2% change in the company's P/S Multiple.| 7312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 0.87 | 0.39 | -55.06% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 28.99 | 34.08 | 17.54% |
| P/S Multiple | 1.55 | 0.85 | -45.23% |
| Shares Outstanding (Mil) | 51.92 | 74.38 | -43.27% |
| Cumulative Contribution | -63.48% |
Market Drivers
7/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| WGRX | -55.1% | |
| Market (SPY) | 7.5% | 7.3% |
| Sector (XLP) | 3.9% | -5.6% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| WGRX | ||
| Market (SPY) | 13.6% | 10.7% |
| Sector (XLP) | 6.3% | 2.7% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2023 to 1/20/2026| Return | Correlation | |
|---|---|---|
| WGRX | ||
| Market (SPY) | 72.9% | 10.7% |
| Sector (XLP) | 20.1% | 2.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| WGRX Return | - | - | - | - | -90% | 2% | -89% |
| Peers Return | 16% | 25% | 22% | 37% | 58% | 1% | 288% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| WGRX Win Rate | - | - | - | - | 27% | 100% | |
| Peers Win Rate | 50% | 60% | 58% | 57% | 67% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| WGRX Max Drawdown | - | - | - | - | -91% | -2% | |
| Peers Max Drawdown | -16% | -14% | -14% | -11% | -0% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | 0% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MCK, COR, CAH, CVS, HIMS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/20/2026 (YTD)
How Low Can It Go
WGRX has limited trading history. Below is the Consumer Staples sector ETF (XLP) in its place.
| Event | XLP | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -17.5% | -25.4% |
| % Gain to Breakeven | 21.2% | 34.1% |
| Time to Breakeven | 682 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -24.9% | -33.9% |
| % Gain to Breakeven | 33.2% | 51.3% |
| Time to Breakeven | 154 days | 148 days |
| 2018 Correction | ||
| % Loss | -16.6% | -19.8% |
| % Gain to Breakeven | 19.9% | 24.7% |
| Time to Breakeven | 404 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -33.4% | -56.8% |
| % Gain to Breakeven | 50.2% | 131.3% |
| Time to Breakeven | 605 days | 1,480 days |
Compare to MCK, COR, CAH, CVS, HIMS
In The Past
SPDR Select Sector Fund's stock fell -17.5% during the 2022 Inflation Shock from a high on 4/20/2022. A -17.5% loss requires a 21.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. In January 2023 and May 2023, Wellgistics Health entered into separate definitive agreements with the owners of Wood Sage and Wellgistics LLC, respectively, whereby Wellgistics Health would acquire all of the respective outstanding membership interests of Wood Sage and Wellgistics LLC. In June 2024, Wellgistics Health and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary of Wellgistics Health. In connection with the Wood Sage Acquisition, Wellgistics Health acquired Wood Sage’s two operating subsidiaries, APS—a pharmaceutical technology hub—and CSP—a retail community specialty pharmacy. On August 30, 2024, Wellgistics Health closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary of Wellgistics Health. As such, Wellgistics Health currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, APS and CSP as indirect operating subsidiaries, and Wellgistics LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Despite that Wellgistics Health only recently closed the Wood Sage Acquisition and the Wellgistics Acquisition during 2024, the three companies have shared common office space, comarketed solutions to the marketplace, and leveraged financial and back-office support prior to June 2024. As such, Wellgistics Health’s management believes that its close business relationships have and will continue to limit the need for post-closing integration. The mailing address of our principal executive office is 3000 Bayport Drive, Suite 950 Tampa, FL.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Wellgistics Health:
- Like a smaller Cardinal Health or McKesson, specializing in B2B distribution of pharmaceuticals and medical supplies.
- Imagine Grainger, but for pharmaceuticals and medical supplies to healthcare facilities.
AI Analysis | Feedback
- Generic Pharmaceutical Distribution: Provides efficient distribution of generic prescription medications to pharmacies, hospitals, and other healthcare providers.
- Branded Pharmaceutical Distribution: Distributes a diverse portfolio of branded prescription drugs to its network of healthcare customers.
- Over-the-Counter (OTC) Product Distribution: Supplies a variety of non-prescription health products and consumer goods to its client base.
- Medical Supply Distribution: Offers distribution services for a range of medical and surgical supplies used by healthcare facilities.
AI Analysis | Feedback
Wellgistics Health (WGRX) Major Customers
Wellgistics Health (WGRX) primarily operates as a wholesale pharmaceutical distributor, selling a wide range of prescription and over-the-counter medications, as well as various healthcare products, to other companies within the healthcare sector. According to their public filings, no single customer accounted for more than 10% of their total net sales for the most recent reporting periods, indicating a diversified customer base. Therefore, specific "major customers" by name are not individually disclosed. However, their primary customer categories, which represent the types of companies they serve, include:- Independent retail pharmacies
- Chain pharmacies
- Hospitals and clinics
- Government agencies
AI Analysis | Feedback
null
AI Analysis | Feedback
Wellgistics Health (symbol: WGRX)Prashant Patel, President, Interim-CEO
Prashant Patel was re-appointed as President, Interim-CEO, and board member of Wellgistics Health on October 13, 2025. He is an entrepreneur and registered Pharmacist with extensive experience in the pharmaceutical supply chain. He founded several startups, including a retail/community pharmacy, before expanding into pharmaceutical distribution and sales, with a focus on pharmaceutical disposal and reverse distribution. Mr. Patel has also consulted for several return logistics pharmaceutical companies over the years. He previously served as a Director, Chief Strategy Officer, and Vice Chairman of the Board of Directors of Wellgistics from 2023 until August 2025. He also served on the board of Scienture after its acquisition of TRxADE Group, Inc..
Eric Sherb, Interim-CFO
Eric Sherb was named Interim-CFO of Wellgistics Health on October 13, 2025. He is a Certified Public Accountant (CPA) with 16 years of experience in accounting advisory, auditing, and mergers and acquisitions, including capital markets experience with IPOs and direct listings. Mr. Sherb is currently the chief financial officer of Crown Reserve Acquisition Corp. I. His previous roles include positions at PricewaterhouseCoopers, RBSM LLP, and CFGI. He also founded and owns EMS Consulting Services, LLC since October 2018 and has worked with several NASDAQ and OTC clients, most recently Scienture Holdings (SCNX), where he previously held the CFO role.
Shelley Bailey, Chief Revenue Officer (CRO)
Shelley Bailey was appointed Chief Revenue Officer in May 2025. She is a growth strategist with deep industry knowledge in scaling healthcare sales teams and revenue operations across multiple verticals. Prior to this role, she served as Chief Strategy Officer at Wellgistics. She was also the Chair of the Oregon Prescription Drug Affordability Board. Between 2020 and 2025, she founded and served as CEO of Famlee Health. From 2000 to 2017, she was CEO and co-owner of Central Drugs Specialty Pharmacy in Oregon.
Srini Kalla, Chief Information Officer (CIO)
Srini Kalla leads the modernization of Wellgistics' digital and data infrastructure, driving the company's AI integration strategy, compliance frameworks, and platform interoperability. Before joining Wellgistics, he worked with Optum Workers' Comp and Auto No-Fault, serving as Executive Director and then Vice President IT. He was also employed in Analyst-Security Operations and Specialist-Operations Support roles at Verizon Data Services. He holds MS and MIS degrees from the University of Florida.
AI Analysis | Feedback
The key risks to Wellgistics Health (WGRX) include its poor financial health, the risk of delisting from Nasdaq, and inherent challenges within the healthcare sector.
- Poor Financial Health and High Debt Burden: Wellgistics Health is characterized by a poor financial strength, marked by significant debt levels and stability concerns. The company has reported substantial operating and net losses, with its operating margin at -115.25% and net margin at -123.31%. Furthermore, the company faces liquidity concerns, as evidenced by a current ratio of 0.32 and a quick ratio of 0.11. Its high debt-to-equity ratio of 27.48 indicates substantial leverage, and an Altman Z-Score of -3.15 places the company in the distress zone, signaling a potential risk of bankruptcy within two years. In late 2025, the company also reported a nine-month net loss of $73.4 million and concluded that these losses, negative operating cash flow, and high leverage raise substantial doubt about its ability to continue as a going concern without additional capital.
- Nasdaq Minimum Bid Price Deficiency and Delisting Risk: Wellgistics Health received a notice from Nasdaq on December 10, 2025, indicating that its common stock failed to meet the minimum closing bid price of $1.00 per share for 30 consecutive business days. This places the company at risk of being delisted from The Nasdaq Capital Market if it cannot regain compliance within the allocated initial 180-day period (until June 8, 2026), or a possible additional 180-day period.
- Sector-Specific Risks and Regulatory/Competitive Pressures: Operating within the healthcare technology and pharmaceutical logistics sector, Wellgistics Health is exposed to significant regulatory and competitive pressures. The company's business model involves navigating FDA regulations, temperature-controlled logistics, and reimbursement rules. Additionally, while Wellgistics Health leverages innovative technologies like AI and blockchain in its pharmaceutical distribution, the adoption of these nascent technologies comes with inherent risks, including potential regulatory scrutiny concerning cryptocurrency use in healthcare.
AI Analysis | Feedback
The clear emerging threat for Wellgistics Health (WGRX) is the increasing presence and potential expansion of major e-commerce and technology companies, most notably Amazon, into the pharmaceutical supply chain. Amazon Pharmacy's established direct-to-consumer prescription delivery service positions it to potentially disintermediate traditional pharmaceutical distributors by leveraging its vast logistics network, technological capabilities, and financial resources to establish its own wholesale and distribution operations, thereby bypassing or significantly reducing the need for third-party distributors like Wellgistics. This mirrors historical disruptions where new entrants with advanced logistics and tech platforms challenged established industry players.
AI Analysis | Feedback
Wellgistics Health (WGRX) operates in several key areas within the United States healthcare sector, addressing substantial markets with its products and services. The primary addressable markets for Wellgistics Health's offerings include:- United States Prescription Drug Market: Wellgistics Health identifies the United States prescription drug market as a significant addressable market, citing its size as $634 billion. Other estimations for the U.S. market for pharmaceutical products valued it at $534 billion in 2020, with projections for growth to nearly $862 billion by 2029. Wellgistics Health also states that its healthcare technology platform is built for the $500 billion prescription drug market.
- Pharmaceutical Distribution Market in the U.S.: The broader pharmaceutical distribution market in the United States is described as a $600 billion market. Wellgistics Health engages in the wholesale and distribution of pharmaceutical products, including generic and branded pharmaceuticals, as well as over-the-counter healthcare and consumer products, primarily to pharmaceutical manufacturers and independent retail pharmacies in the United States.
- Telemedicine Remote Dispensing Market: In relation to its acquisition of Kare Rx Hub, Wellgistics Health operates within the telemedicine remote dispensing market, which is projected to grow from $6.7 billion in 2025 to $13.57 billion by 2032 in the United States.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Wellgistics Health (WGRX)
- Expansion of Manufacturer Relationships and Product Portfolio: Wellgistics Health is actively expanding its relationships with pharmaceutical manufacturers, which in turn broadens its product offerings. The company reported accelerating platform growth in Q2 with 116 new manufacturer partnerships and the addition of over 12,400 new products. This expansion directly increases the range of pharmaceuticals and healthcare products available for distribution, driving potential sales volume.
- Growth in Pharmacy Network and Onboarding: The company is focused on increasing its customer base by registering new pharmacies. In the first quarter of 2025, Wellgistics Health registered 354 new pharmacies, with a significant portion already placing orders. The network has expanded to include over 6,500 independent pharmacies, indicating a growing reach for its distribution services and a larger customer base for its products.
- Enhancement and Expansion of Technology Infrastructure: Wellgistics Health is investing in and expanding its technology platforms. Key initiatives include the planned expansion of its Peek platform, the introduction of HubRx AI as an AI-powered prescription ecosystem, and the recent launch of EinsteinRx, a platform designed to revolutionize prescription management. The company is also advancing its AI-driven prescription routing technology. These technological advancements aim to improve operational efficiency, attract new partners, and create new revenue opportunities through innovative healthcare solutions.
- Scaling Direct-to-Patient (DTP) Programs: Wellgistics Health is strategically scaling its direct-to-patient programs. The company aims to expand these programs into therapeutic areas such as diabetes, weight loss, and chronic pain. This focus represents an expansion into new service lines that could unlock additional revenue streams by directly connecting patients with necessary medications and services.
AI Analysis | Feedback
Share Issuance
- In February 2025, Wellgistics Health completed its Initial Public Offering (IPO), issuing 888,889 shares of common stock at $4.50 per share, which generated $4.0 million in gross proceeds.
- Wellgistics Health conducted a public offering in September 2025, pricing 7,142,862 shares of common stock along with warrants to purchase an equal number of shares at $0.70 per share, aiming to raise approximately $5 million.
- During 2025, the company executed debt-to-equity conversions totaling $10.1 million to strengthen its balance sheet and improve financial flexibility. This included an $8.1 million conversion approved in July 2025 and further conversions on October 30, 2025, amounting to approximately $5.3 million.
Outbound Investments
- Wellgistics Health acquired Wood Sage LLC on June 16, 2024, and Wellgistics LLC on August 30, 2024, as part of its strategy to build an integrated healthcare ecosystem.
- In April 2025, Wellgistics Health announced an agreement to acquire Peek Healthcare Technologies, Inc., which operates the Peek Meds Marketplace, to enhance digital healthcare and prescription price transparency.
- The company entered into a non-binding letter of intent in November 2025 to acquire Kare Rx Hub, an AI-based digital pharmacy hub, in an all-stock transaction slated to close by January 31, 2026.
Capital Expenditures
- Proceeds from the February 2025 IPO were designated for general corporate purposes, including capital expenditures.
- A $1.3 million loan was secured in August 2025 with the intention of bolstering healthcare technology initiatives.
- The net proceeds from the September 2025 public offering are intended for working capital, operating expenses, research and development, and potential acquisitions, which may involve capital expenditures.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Wellgistics Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 145.23 |
| Mkt Cap | 59.0 |
| Rev LTM | 271,955 |
| Op Inc LTM | 3,128 |
| FCF LTM | 2,529 |
| FCF 3Y Avg | 3,219 |
| CFO LTM | 3,136 |
| CFO 3Y Avg | 3,757 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 13.3% |
| Rev Chg 3Y Avg | 10.4% |
| Rev Chg Q | 6.9% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Mgn LTM | 1.3% |
| Op Mgn 3Y Avg | 1.2% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 1.5% |
| CFO/Rev 3Y Avg | 1.7% |
| FCF/Rev LTM | 1.3% |
| FCF/Rev 3Y Avg | 1.4% |
Price Behavior
Price Behavior
| Market Price | $0.39 | |
| Market Cap ($ Bil) | 0.0 | |
| Distance from 52W High | -92.1% | |
| 50 Days | 200 Days | |
| DMA Price | $2.10 | $2.10 |
| DMA Trend | down | down |
| Distance from DMA | -81.4% | -81.4% |
| 3M | 1YR | |
| Volatility | 401.7% | 260.3% |
| Downside Capture | 198.27 | 268.25 |
| Upside Capture | 236.35 | -20.10 |
| Correlation (SPY) | 13.0% |
WGRX Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.26 | 2.46 | 3.38 | 2.34 | -0.78 | -0.07 |
| Up Beta | -6.66 | 1.02 | 5.78 | 6.67 | 0.27 | -1.84 |
| Down Beta | 1.95 | 5.75 | 1.19 | 1.77 | 0.57 | -0.15 |
| Up Capture | -213% | -69% | -36% | -59% | -15% | -2% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 10 | 19 | 25 | 48 | 81 | 81 |
| Down Capture | 573% | 331% | 313% | 159% | 149% | 97% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 12 | 22 | 39 | 77 | 130 | 130 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullEarnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/20/2025 | 2.4% | 14.4% | -12.4% |
| 8/22/2025 | 73.5% | 30.2% | 7.9% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 1 |
| # Negative | 0 | 0 | 1 |
| Median Positive | 37.9% | 22.3% | 7.9% |
| Median Negative | -12.4% | ||
| Max Positive | 73.5% | 30.2% | 7.9% |
| Max Negative | -12.4% | ||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/19/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/19/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/12/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/25/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 02/21/2025 | 424B4 (09/30/2024) |
| 06/30/2024 | 09/27/2024 | S-1/A (06/30/2024) |
| 03/31/2024 | 07/22/2024 | S-1 (03/31/2024) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.